A Guide to Cause, Consequence, and Cellular Stress
Mitochondrial changes appear in many diseases, but their meaning differs from one condition to another. In some inherited disorders, mitochondrial dysfunction is the direct cause. In others, it may be a contributor, a consequence, an adaptation, or part of a feedback loop.
A framework for understanding mitochondrial involvement in disease
This guide explains how researchers interpret mitochondrial findings across genetic, metabolic, cardiovascular, neurological, inflammatory, and malignant diseases.
The central distinction is between primary mitochondrial diseases, where impaired mitochondrial function is central to a genetically defined disorder, and secondary mitochondrial dysfunction, where mitochondrial changes occur within another disease process.
Read the chapters in order or use the contents to return directly to a disease group, biological concept, or area of research you want to examine in greater detail.
This guide is educational, not diagnostic. Fatigue, weakness, cognitive changes, exercise intolerance, and poor recovery can have many causes and do not, by themselves, establish a mitochondrial disorder.
What Does Mitochondrial Dysfunction Mean?
Mitochondrial dysfunction is not one disease, one laboratory value, or one uniform biological state. It is an umbrella term for several different changes in mitochondrial structure, function, regulation, or cellular signaling.
Mitochondria are best known for helping convert energy from nutrients into adenosine triphosphate, or ATP. Cells use ATP to support contraction, electrical signaling, transport, biosynthesis, maintenance, and repair.
Their role extends beyond ATP production. Mitochondria also help regulate fuel selection, calcium movement, redox signaling, immune activity, cellular stress responses, quality control, and programmed cell death.
When researchers describe mitochondrial dysfunction, they must therefore identify what changed, in which cells, at what point in a disease process, and whether the change appears harmful, protective, compensatory, or unresolved.
Possible findings
What researchers may mean by mitochondrial dysfunction
The term can refer to one or several cellular changes. These findings are related, but they are not interchangeable and do not necessarily occur together.
Reduced ATP-producing capacity
A cell may be less able to increase ATP production when demand rises, even if energy production appears adequate at rest.
Altered fuel use
Cells may process glucose, fatty acids, amino acids, or other substrates differently or become less able to switch among fuels.
Disrupted redox signaling
Reactive oxygen species may become excessive, poorly controlled, or insufficiently balanced by antioxidant and repair systems.
Disturbed calcium handling
Mitochondria may take up, release, or buffer calcium abnormally, affecting signaling, contraction, metabolism, and cell survival.
Changes in shape and network dynamics
Mitochondrial fission, fusion, distribution, movement, or internal structure may change in response to stress or disease.
Impaired quality control
Cells may become less effective at repairing mitochondrial components or removing damaged mitochondria through mitophagy.
Mitochondrial DNA changes
The abundance, integrity, sequence, or tissue distribution of mitochondrial DNA may differ from what is expected.
Altered signaling with the nucleus
Communication between mitochondria and nuclear genes may change, affecting metabolism, stress responses, repair, and adaptation.
Abnormal inflammatory or cell-death signaling
Mitochondrial stress signals, damaged mitochondrial components, or changes in membrane integrity may influence inflammation, apoptosis, or other cell-death pathways.
An important distinction
These findings are not interchangeable
A cell can show normal ATP production but abnormal calcium handling. Another cell may contain fewer mitochondria while each remaining mitochondrion retains normal respiratory capacity.
A third cell may temporarily increase mitochondrial activity in response to nutrient excess, inflammation, exercise, or another form of stress. Increased activity is not automatically healthier, and reduced activity is not automatically harmful.
Mitochondrial abundance, respiratory capacity, ATP output, membrane potential, redox state, and quality control describe different features. A conclusion about one feature should not be expanded into a claim about the entire mitochondrial system.
Measurement note
Different tests answer different questions
A genetic test, blood marker, muscle biopsy, imaging study, cell-culture experiment, and respiratory assay do not measure the same aspect of mitochondrial biology.
Results can differ according to tissue, cell type, age, disease stage, physical activity, medication exposure, sample handling, and the nutrients supplied during laboratory testing.
A result from circulating blood cells may not describe mitochondrial function in the brain, heart, skeletal muscle, liver, or kidney. Findings from one selected tissue also should not automatically be generalized to the entire body.
Primary Mitochondrial Disease and Secondary Dysfunction
The phrase mitochondrial disease has a specific clinical meaning. It should not be used as a general label for every condition in which researchers have observed mitochondrial changes.
Primary mitochondrial disease
Primary mitochondrial diseases are caused by pathogenic genetic variants that disrupt mitochondrial function in a way that is central to the disorder.
The variant may be located in mitochondrial DNA or in nuclear DNA. Most of the genes needed to build, maintain, regulate, and reproduce mitochondria are located in the cell nucleus.
- Mitochondrial dysfunction is central to the disease.
- The condition may affect one organ or several organ systems.
- Diagnosis usually requires clinical and molecular genetic evidence.
- Symptoms and severity can vary widely among affected people.
Secondary mitochondrial dysfunction
Secondary mitochondrial dysfunction refers to mitochondrial changes that develop within another disease, injury, exposure, or physiological stress.
These changes may arise from inflammation, reduced oxygen delivery, metabolic overload, abnormal proteins, medication exposure, tissue damage, or altered cellular signaling.
- Another condition begins the broader disease process.
- Mitochondrial changes may contribute to progression.
- They may also be consequences or temporary adaptations.
- Their role can differ by tissue and disease stage.
A practical comparison
Primary and secondary are not interchangeable
Both categories can involve measurable mitochondrial abnormalities, but the origin, diagnostic meaning, and clinical interpretation are different.
| Feature | Primary mitochondrial disease | Secondary mitochondrial dysfunction |
|---|---|---|
| What begins the process? | A pathogenic mitochondrial-DNA or nuclear-DNA variant affecting mitochondrial biology. | Another illness, injury, exposure, medication, or physiological stress. |
| Relationship to the condition | Mitochondrial impairment is central to the disorder. | Mitochondrial changes may be contributors, consequences, adaptations, feedback mechanisms, or associations. |
| Typical clinical pattern | Often multisystem, although some disorders show strong tissue selectivity. | Depends on the underlying disease, affected tissue, severity, and stage. |
| Diagnostic approach | Clinical assessment, molecular genetics, and selected biochemical, imaging, or tissue studies. | Evaluated within the diagnosis and biology of the underlying condition; it is not one separate universal diagnosis. |
| Examples | MELAS, MERRF, Leigh syndrome spectrum, LHON, POLG-related disorders, and mitochondrial myopathies. | Mitochondrial changes reported in diabetes, heart failure, chronic kidney disease, cancer, and neurodegenerative disease. |
A person with fatigue, diabetes, heart failure, neurological symptoms, or another common condition does not automatically have a primary mitochondrial disease.
Why presentation varies
Heteroplasmy and threshold effects
Each cell can contain many mitochondria and many copies of mitochondrial DNA. When normal and altered mitochondrial DNA coexist, the condition is called heteroplasmy.
The proportion of altered mitochondrial DNA can differ among blood, muscle, brain, liver, kidney, urine, and other tissues. It may also change with age.
This tissue distribution helps explain why a mitochondrial-DNA variant can affect one organ more severely than another and why a blood test may not always detect a variant that is more abundant in another tissue.
Primary disease examples
A family of genetically diverse disorders
Named mitochondrial syndromes are useful clinical patterns, but they do not always correspond to one gene, one mutation, or one fixed set of symptoms.
MELAS
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes is a genetically defined syndrome with variable neurological, muscular, endocrine, hearing, and other systemic features. Its stroke-like episodes are not the same as ordinary vascular strokes caused by a blocked artery.
MERRF
Myoclonic epilepsy with ragged-red fibers can involve myoclonus, epilepsy, ataxia, hearing loss, weakness, and myopathy. Clinical expression varies, and not every affected person has the complete classic presentation.
Leigh syndrome spectrum
Leigh syndrome spectrum is defined by a characteristic clinical and neuroimaging pattern. It can result from pathogenic variants in many nuclear genes and from some mitochondrial-DNA variants. It is not one single molecular disease.
Leber hereditary optic neuropathy
LHON is caused by pathogenic mitochondrial-DNA variants and primarily affects retinal ganglion cells. Penetrance is incomplete, meaning that not every person who carries a pathogenic variant develops visual loss.
Mitochondrial myopathy
Mitochondrial myopathies primarily affect skeletal muscle and can cause exercise intolerance, weakness, cramps, or fatigue. Similar symptoms occur in many non-mitochondrial conditions, so diagnosis cannot be based on symptoms alone.
Cause, Contributor, Consequence, Adaptation, or Feedback Loop?
Finding a mitochondrial difference in a disease does not, by itself, reveal where mitochondria sit in the disease process. The change may initiate the condition, help drive it, result from it, compensate for it, or participate in a two-way relationship.
Researchers can measure changes in mitochondrial respiration, structure, DNA, fuel use, signaling, and quality control. These observations are important, but an observation is not the same as an explanation.
Interpretation depends on timing, tissue, disease stage, biological context, and experimental method.
A mitochondrial change that appears after a disease is established may still worsen symptoms or progression. It should not, however, be described as the original cause unless stronger evidence supports that conclusion.
Interpretation framework
Seven possible relationships between mitochondria and disease
These are categories, not stages or rankings. More than one relationship may be present in the same condition.
Direct cause
A pathogenic genetic variant disrupts an essential mitochondrial process and causes a defined disorder. Primary mitochondrial diseases are the clearest examples.
Established contributor
Genetic, molecular, and functional evidence links a specific mitochondrial pathway to a defined disease subtype. That evidence should not automatically be generalized to every person with the broader condition.
Contributor and consequence
The disease environment alters mitochondrial function, while the resulting mitochondrial changes may further affect tissue performance, metabolism, signaling, or recovery.
Compensatory response
Cells alter mitochondrial activity, abundance, shape, or fuel use to manage a new demand or stress. A response can differ from the healthy baseline while remaining temporarily helpful.
Reinforcing loop
Mitochondrial stress, inflammation, tissue damage, calcium imbalance, oxidative stress, or weakened quality control reinforce one another over time.
Altered metabolic strategy
Cells reorganize mitochondrial activity, nutrient use, and biosynthesis to support a changed biological state. This is especially important in cancer, where mitochondria may actively support growth and survival.
Mixed or inconsistent evidence
Findings differ by tissue, cell type, disease stage, laboratory method, treatment exposure, or patient subgroup. A confident causal conclusion is not yet justified.
Evaluating a claim
Three questions help separate observation from conclusion
Strong claims require evidence that goes beyond finding a difference between diseased and healthy cells.
Is there evidence that it helps drive the disease?
Does genetic, longitudinal, or experimental evidence show that the mitochondrial change precedes or meaningfully influences the disease process?
Has the finding been reproduced?
Does it appear across independent studies, relevant tissues, appropriate comparison groups, and comparable stages of disease?
Does changing it improve meaningful outcomes?
Does modifying the pathway improve symptoms, function, progression, survival, or another clinical outcome—not only a laboratory measurement?
Applying the framework
The most accurate interpretation differs by condition
These examples show why one phrase—“mitochondrial dysfunction”—cannot describe every disease relationship.
A pathogenic variant directly disrupts mitochondrial biology and is central to the genetically defined disorder.
Mitophagy and mitochondrial quality-control pathways have a direct genetic connection in these defined forms. This does not establish the same mechanism in every case of Parkinson disease.
Metabolic or hemodynamic stress can alter mitochondrial function, while mitochondrial changes may add further strain. Findings vary by tissue, stage, and disease subtype.
Cancer often involves active metabolic reprogramming, while conditions such as sepsis or ME/CFS may show mixed mitochondrial findings across cell types, time points, and patient groups.
Why Some Tissues Are More Vulnerable
Mitochondrial changes do not affect every cell in the same way. Vulnerability depends on what a tissue must do, how much reserve it has, and how effectively it can adapt, repair, or replace damaged cells.
Every nucleated human cell depends on mitochondria, but tissues use them differently. A contracting heart cell, a signaling neuron, a kidney tubule cell, and an activated immune cell do not have the same metabolic requirements.
Tissues also differ in their ability to tolerate disruption. Some cells can reduce activity, change fuel use, or be replaced. Others must continue highly specialized work with little interruption.
This helps explain why the same genetic or biological change can affect the brain, muscle, vision, hearing, heart, or endocrine system differently.
What the tissue must sustain
Continuous contraction, electrical signaling, active transport, and biosynthesis can require a steady supply of ATP and tightly regulated mitochondrial signaling.
What stresses the tissue faces
Oxygen limitation, nutrient excess, inflammation, toxins, abnormal proteins, and repeated mechanical or metabolic demand can affect mitochondrial function.
How well the tissue can respond
Reserve capacity, quality control, cellular replacement, and the ability to alter fuel use influence whether a tissue compensates or loses function.
Tissue atlas
Mitochondrial demands differ across the body
These examples show why mitochondrial findings must be interpreted within the biology of the specific tissue being studied.
Signaling and maintenance
Neurons require energy for ion gradients, neurotransmission, calcium regulation, cellular transport, and maintenance of synaptic connections.
Cell types and regions differ
Neurons, astrocytes, microglia, and different brain regions use fuels differently and may not show the same mitochondrial pattern.
Continuous contraction
Heart muscle relies on mitochondria for ATP production, calcium cycling, membrane stability, and the ability to use different fuels.
Subtype and method matter
Tissue samples, isolated mitochondria, imaging, and different forms of heart disease can produce different findings.
Movement and adaptation
Muscle must rapidly adjust energy production as activity changes. Mitochondria also support calcium regulation, fuel selection, exercise adaptation, and recovery.
Activity changes the measurement
Fiber type, training, inactivity, age, and recent exercise all influence mitochondrial abundance and function.
Energy-intensive transport
Kidney cells use energy to move nutrients and electrolytes while maintaining fluid, acid-base, and metabolic balance.
Kidney regions are specialized
Tubular, glomerular, and other kidney cells differ in fuel use, oxygen exposure, and susceptibility to injury.
Metabolic coordination
The liver processes nutrients, manages glucose and lipids, supports detoxification, and adapts metabolism between feeding and fasting.
Context strongly affects results
Nutrition, insulin resistance, alcohol, medications, inflammation, and disease stage can alter mitochondrial measurements.
Rapid metabolic shifts
Immune cells reorganize fuel use and mitochondrial activity as they activate, migrate, communicate, resolve inflammation, or form immune memory.
Direction depends on timing
Increased or reduced respiration may both be meaningful, depending on the cell type, activation state, and stage of the immune response.
Disease overview
Mitochondrial involvement across major disease groups
This overview provides orientation before the disease-specific chapters. It does not rank conditions or measure how strongly mitochondria cause each disease.
Population estimates use different years, definitions, and methods. They provide scale only and should not be compared as though they came from one dataset.
| Condition | Approximate burden | Possible mitochondrial role | Interpretation |
|---|---|---|---|
| Primary mitochondrial disease | |||
| Primary mitochondrial disease | About 1 in 4,300 adults Regional UK adult estimate; not global. | Pathogenic mitochondrial- or nuclear-DNA variants directly impair mitochondrial biology. | Mitochondrial dysfunction is central to a genetically defined disorder. |
| Metabolic, liver, and reproductive-metabolic disease | |||
| Obésité | More than 1 billion people Global estimate for 2022. | Nutrient handling, fatty-acid metabolism, adipose signaling, and inflammation may interact. | Human findings vary. Mitochondrial impairment is not required for every form of obesity or insulin resistance. |
| Diabetes | About 589 million adults Ages 20–79 in 2024; all diabetes types. | Fuel processing, beta-cell function, redox signaling, and tissue-specific adaptation may change. | Findings differ by diabetes type, tissue, stage, and treatment. |
| MASLD and MASH | Approximately 1.3 billion people Modeled MASLD estimate for 2023. | Fatty-acid oxidation, respiratory adaptation, redox stress, and inflammation may interact. | Mitochondrial changes may influence progression without necessarily initiating liver-fat accumulation. |
| Polycystic ovary syndrome | About 10%–13% Reproductive-aged women. | Metabolism, redox signaling, steroid production, and granulosa-cell function have been studied. | Direct evidence comes from selected cohorts and cell studies; certainty remains limited. |
| Cardiovascular, kidney, and ischemic disease | |||
| Chronic kidney disease | Approximately 674 million people Approximate global estimate. | Transport demand, oxygen use, fuel metabolism, inflammation, fibrosis, and quality control may be affected. | The relationship differs by kidney region, disease cause, and stage. |
| Heart failure | More than 64 million adults Approximate worldwide estimate. | Fuel use, ATP supply, calcium cycling, redox balance, and mitochondrial structure may be remodeled. | Results differ by heart-failure subtype and testing method. |
| Stroke | 93.8 million prevalent cases About 11.9 million new strokes in 2021. | Interrupted oxygen delivery disrupts ATP production, ion balance, calcium control, and cell survival. | Reperfusion is essential for tissue rescue even though it can add oxidative and inflammatory injury. |
| Neurological disease | |||
| Dementia | About 57 million people All dementias in 2021; not Alzheimer disease alone. | Energy metabolism, calcium, redox signaling, transport, and quality control may change. | Mitochondrial changes occur within a complex process; causal priority remains unresolved in common sporadic disease. |
| Parkinson disease | More than 8.5 million people Global estimate for 2019. | Respiration, mitophagy, calcium, oxidative stress, and neuronal quality control may be involved. | Defined genetic pathways such as PINK1 and PRKN do not explain every case. |
| Cancer | |||
| Cancer | About 53.5 million people Alive within five years of diagnosis in 2022. | Tumors may reorganize respiration, nutrient use, biosynthesis, redox balance, and stress responses. | Many cancers retain active mitochondria; the process is better described as metabolic reprogramming than universal failure. |
These examples are not exhaustive. The following chapters examine the evidence and limitations for each disease group in greater detail.
Metabolic, Liver, and Reproductive-Metabolic Disease
Metabolic diseases involve interactions among nutrient availability, hormones, tissue demand, inflammation, fat storage, and organ-specific adaptation. Mitochondria participate in these processes, but their role differs across conditions, tissues, and stages of disease.
Mitochondria help cells process carbohydrates, fats, and amino acids. They also influence insulin secretion, steroid production, redox signaling, inflammation, and the ability to adapt between feeding, fasting, activity, and rest.
Metabolic stress does not always begin with mitochondrial failure. In some situations, mitochondria initially increase activity to manage an excess supply of nutrients. In others, altered mitochondrial function develops after inflammation, fat accumulation, hormonal disruption, or tissue injury is already present.
The relevant question is therefore not simply whether mitochondria change, but what changed, in which tissue, at what stage, and whether the response is compensatory or harmful.
Nutrient load and flexibility
Cells may need to process sustained supplies of glucose and fatty acids or switch among fuels as feeding, fasting, and activity change.
Hormonal and cellular communication
Insulin, reproductive hormones, adipose signals, and inflammatory pathways influence how tissues store, release, and use energy.
Adaptation, stress, and repair
Mitochondrial activity may initially compensate for increased demand but later become part of oxidative stress, inflammation, or tissue injury.
Obésité
Obesity is biologically diverse. Adipose distribution, genetics, diet, physical activity, sleep, medications, endocrine factors, and the health of individual tissues all influence its metabolic effects.
Findings differ among tissues
Studies report changes in mitochondrial abundance, respiration, fatty-acid processing, structure, and redox signaling in adipose tissue, skeletal muscle, and liver.
Fuel handling and tissue signaling
Mitochondrial changes may influence lipid storage, adipocyte function, inflammatory signaling, fuel flexibility, and how tissues respond to nutrient excess.
Adaptation, consequence, or contributor
Some changes may initially help tissues manage excess fuel. Others may develop as adipose dysfunction or inflammation progresses and then add further metabolic strain.
Human findings are heterogeneous
Preserved, reduced, or increased mitochondrial capacity has been reported. Mitochondrial impairment is not required for every form of obesity or insulin resistance.
Diabetes
Diabetes includes distinct diseases. Type 1 diabetes, type 2 diabetes, gestational diabetes, and other forms should not be treated as one mitochondrial mechanism.
Changes vary by tissue and stage
Mitochondrial findings have been reported in pancreatic beta cells, skeletal muscle, liver, adipose tissue, kidney, nerves, and other tissues affected by diabetes.
Insulin secretion and fuel processing
In beta cells, mitochondrial ATP production helps connect glucose sensing to insulin secretion. In other tissues, mitochondrial pathways influence fuel use, redox balance, and metabolic adaptation.
Stage-dependent and bidirectional
Early nutrient excess may increase substrate oxidation and mitochondrial stress. Later disease may involve reduced capacity, tissue damage, or altered quality control.
One result cannot describe all diabetes
Findings differ with diabetes type, duration, glucose control, medication exposure, complications, physical activity, and the tissue examined.
MASLD and MASH
Metabolic dysfunction-associated steatotic liver disease, or MASLD, involves excess liver fat in a metabolic context. MASH refers to the inflammatory and injurious form that can progress toward fibrosis.
Adaptation can precede impairment
Early liver-fat accumulation may be accompanied by increased fatty-acid oxidation. More advanced disease may show respiratory inefficiency, redox stress, membrane injury, and weaker quality control.
Lipid handling, stress, and injury
Mitochondrial pathways may influence how the liver processes fatty acids, manages oxidative stress, responds to inflammation, and maintains cell survival.
Adaptation followed by possible feedback
Mitochondrial changes may help the liver manage excess fuel initially, then contribute to inflammation or injury if the metabolic burden continues.
Involvement does not prove initiation
Mitochondrial changes may participate in progression without being the original cause of liver-fat accumulation. Findings also differ by disease stage and research method.
Metabolic Syndrome and Dyslipidemia
These terms are often discussed together, but they should not share one prevalence estimate or be treated as the same diagnosis.
Metabolic syndrome
Metabolic syndrome describes a defined cluster that may include central adiposity, elevated blood pressure, abnormal glucose, high triglycerides, and reduced HDL cholesterol.
Researchers study mitochondrial fuel use, redox signaling, and tissue adaptation within this broader metabolic context.
It is a clinical risk framework, not one uniform mitochondrial disease mechanism.
Dyslipidemia
Dyslipidemia refers to abnormal levels or patterns of circulating cholesterol, triglycerides, and lipoproteins. Definitions and patterns vary.
Mitochondria participate in fatty-acid oxidation and lipid metabolism, but dyslipidemia can arise through many genetic, dietary, hormonal, hepatic, and medication-related pathways.
No single global patient count should be assigned without a specific definition and population.
Polycystic Ovary Syndrome
Polycystic ovary syndrome, or PCOS, is a heterogeneous condition involving reproductive, hormonal, and metabolic features. Not every person with PCOS has the same symptoms or metabolic profile.
Selected cellular differences
Studies of granulosa cells and selected patient groups have reported differences in membrane potential, mitochondrial DNA, ATP-related pathways, redox signaling, and mitochondrial dynamics.
Steroid production and metabolic signaling
Mitochondria support steroid-hormone synthesis and cellular metabolism. They may interact with insulin resistance, oxidative stress, and ovarian-cell function.
Possible contributor or consequence
Mitochondrial changes may contribute to cellular stress, arise from the hormonal and metabolic environment, or participate in a two-way relationship.
Direct evidence remains limited
Much of the evidence comes from selected cohorts, ovarian cells, and laboratory studies. Diagnostic heterogeneity and small samples limit causal conclusions.
Cardiovascular, Kidney, and Ischemic Disease
The heart and kidneys perform continuous, energy-intensive work and depend on tightly regulated blood flow, oxygen delivery, fuel use, and cellular transport. Mitochondrial changes may emerge as these systems adapt to chronic stress or respond to an abrupt interruption in blood supply.
Cardiovascular and kidney diseases do not share one mitochondrial mechanism. Pressure overload, impaired circulation, diabetes, genetic cardiomyopathy, inflammation, fibrosis, toxin exposure, and ischemia place different demands on cells.
In chronic disease, mitochondria may gradually remodel their fuel use, structure, respiratory capacity, and quality-control systems. In acute ischemia, oxygen loss can cause ATP production to fall rapidly.
Interpretation therefore depends on whether the evidence concerns chronic adaptation, progressive tissue damage, an acute loss of blood flow, or the response after circulation is restored.
Continuous energy demand
The heart contracts continuously, while kidney tubules sustain active transport. Both require ATP, regulated calcium, intact membranes, and the ability to respond when demand changes.
Oxygen and fuel delivery
Blood flow must deliver oxygen and metabolic substrates while removing waste. Reduced supply can limit mitochondrial respiration and alter ion balance, redox state, and cell survival.
Remodeling and repair
Cells may change fuel preference, mitochondrial structure, quality control, and signaling to compensate. The response can become insufficient or contribute to further damage as disease advances.
Chronic disease
Similar organ demands, different disease relationships
Each condition must be interpreted according to the tissue sampled, disease subtype, stage, and measurement used.
Heart failure
Cardiac metabolism is remodeled
Human studies have reported changes in mitochondrial shape, internal structure, fuel use, respiratory enzymes, calcium handling, and quality-control pathways.
Energy supply must match mechanical work
The failing heart must continue contracting despite altered loading, reduced reserve, impaired relaxation, or damaged tissue. Mitochondrial remodeling may affect that capacity.
Results differ by subtype and method
Heart failure with preserved ejection fraction and heart failure with reduced ejection fraction are not the same condition. Tissue studies and isolated-mitochondria tests may also give different results.
Cardiomyopathy
A group of different diseases
Cardiomyopathy includes hypertrophic, dilated, restrictive, arrhythmogenic, mitochondrial, and other forms of heart-muscle disease.
Findings can be subtype-specific
Human hypertrophic-cardiomyopathy tissue has shown altered respiration and mitochondrial organization, but the findings vary with genetic status and myocardial remodeling.
Name the cardiomyopathy
Evidence from one subtype should not be presented as the mechanism of all cardiomyopathies. In primary mitochondrial cardiomyopathy, the genetic relationship is more direct.
Chronic kidney disease
Tubular metabolism is frequently studied
Kidney research has reported changes in fatty-acid oxidation, respiration, mitochondrial structure, quality control, inflammatory signaling, and cell-death pathways.
Transport requires sustained ATP
Tubular cells use energy to reclaim nutrients and electrolytes. Reduced oxygen supply, metabolic disease, toxins, and inflammation can interfere with that work.
Kidney regions are not interchangeable
Proximal tubules, glomerular cells, collecting ducts, and other kidney compartments differ in fuel use, oxygen exposure, function, and vulnerability.
Acute loss and restoration of blood flow
Ischemia and reperfusion unfold over time
Ischemic stroke and myocardial infarction can involve an abrupt reduction or interruption in blood flow. The injury begins during ischemia, while the restoration of circulation creates a second, biologically distinct phase.
Oxygen supply falls
Oxidative phosphorylation slows, ATP availability declines, and cells become less able to maintain ion gradients. Sodium and calcium imbalance, acidosis, swelling, and membrane stress begin to develop.
Blood flow returns
Oxygen and nutrients become available again, but damaged mitochondria may produce a burst of reactive species, lose membrane stability, and release signals that activate inflammation and cell-death pathways.
Tissue outcome develops
Surviving cells attempt repair and metabolic recovery. Persistent inflammation, microvascular dysfunction, mitochondrial damage, and cell loss can influence neurological recovery or cardiac remodeling.
From mechanism to treatment
Promising mitochondrial targets have not always improved outcomes
Reperfusion injury has strong biological plausibility, but clinical trials show why mechanistic promise must be tested directly in patients.
TRO40303 during acute myocardial infarction
TRO40303 was intended to reduce mitochondrial permeability-related injury when administered before coronary blood flow was restored during primary percutaneous coronary intervention.
The trial did not show a significant reduction in infarct size, myocardial salvage, or left-ventricular function compared with placebo.
Cyclosporine before coronary reperfusion
Cyclosporine was studied as a way to limit mitochondrial permeability-transition-related injury in patients with anterior ST-elevation myocardial infarction.
The larger trial did not improve the combined clinical outcome or prevent adverse left-ventricular remodeling at one year.
Neurological and Neuromuscular Disease
The nervous system depends on tightly regulated energy production, calcium buffering, mitochondrial transport, protein quality control, and synaptic maintenance. Mitochondrial pathways are therefore studied across many neurological diseases, but the strength and meaning of the evidence differ sharply.
Neurons must maintain electrical gradients, communicate across synapses, and transport proteins and organelles along axons that may extend over long distances. Many neurons must perform this work for an entire lifetime.
Mitochondrial changes can therefore influence neuronal energy, calcium control, redox signaling, axonal transport, inflammation, and cell survival. The presence of these changes does not mean that every neurological disease begins with mitochondrial failure.
The strongest interpretation depends on whether the evidence comes from a causal gene, human brain tissue, imaging, patient cells, animal models, or a selected clinical subgroup.
Evidence relationship map
The conditions do not occupy the same scientific category
These categories describe the most appropriate current interpretation. They are not rankings of disease severity or importance.
Friedreich ataxia
Frataxin deficiency directly disrupts mitochondrial iron–sulfur cluster biology and related cellular functions.
Selected Parkinson disease
PINK1-, PRKN-, and related genetic forms provide direct evidence for mitochondrial quality-control pathways.
Alzheimer disease, MS, ALS, and Huntington disease
Mitochondrial changes may add to neuronal injury but do not replace the established or broader disease process.
Autism-related metabolic findings
Mitochondrial or metabolic abnormalities may be relevant to a subset of autistic people, not autism as a whole.
Epilepsy can appear in more than one category: it may be a direct manifestation of a primary mitochondrial disorder or a source of secondary metabolic stress during repeated seizures.
Major neurological profiles
What human evidence shows—and what it does not
Each profile separates the observed mitochondrial finding from the limit on the conclusion that can be drawn.
Dementia and Alzheimer Disease
Contributor and consequenceBrain-energy and complex I changes
Human imaging studies using markers of mitochondrial complex I have reported associations with regional hypometabolism, tau pathology, brain atrophy, and cognitive symptoms in Alzheimer disease.
Several processes may interact
Mitochondrial metabolism may interact with amyloid, tau, vascular injury, inflammation, calcium signaling, synaptic dysfunction, and neuronal loss.
Parkinson Disease
Defined pathways and broader involvementGenetics connects quality control to disease
PINK1, Parkin, and related genes provide direct evidence that mitochondrial quality-control pathways contribute to defined genetic forms of Parkinson disease.
Human brain studies show complex I abnormalities
Studies of affected brain regions have reported complex I damage or impaired assembly. Mitochondrial transport, turnover, calcium, and oxidative stress are also under investigation.
Sclérose en plaques
Contributor in selected lesionsRespiratory defects occur in some acute lesions
Human tissue studies have identified mitochondrial respiratory-chain defects in subsets of acute multiple sclerosis lesions.
Energy failure may add to axonal injury
Demyelinated axons can face increased energy demand. Mitochondrial impairment within an inflammatory lesion may reduce the axon’s ability to maintain ion balance and survive.
Amyotrophic Lateral Sclerosis
Downstream contributor under studyTransport, calcium, dynamics, and quality control
Research examines mitochondrial movement along axons, fission and fusion, calcium handling, quality control, redox stress, and cell-death pathways.
Models provide much of the mechanistic evidence
A substantial part of the evidence comes from cellular and animal models, particularly models involving SOD1-related disease.
Genetic and neuromuscular distinctions
The causal gene determines how mitochondria fit into the disease
These conditions illustrate three different relationships: a downstream consequence of a known disease gene, a direct disease-specific mitochondrial mechanism, and a manifestation that can have either primary or secondary origins.
Huntington Disease
Huntington disease is caused by an expanded CAG repeat in the HTT gene. Changes in energy metabolism, mitochondrial dynamics, calcium handling, and mitochondrial DNA may occur downstream and contribute to neuronal dysfunction.
Mitochondrial changes may contribute to disease biology, but they do not replace the established genetic cause.
Friedreich Ataxia
Friedreich ataxia is usually caused by alterations in the nuclear FXN gene that reduce frataxin. Frataxin deficiency disrupts mitochondrial iron–sulfur cluster biology, energy metabolism, redox balance, and cellular stress responses.
This is a direct mitochondrial mechanism even though the causal gene is located in nuclear DNA rather than mitochondrial DNA.
Epilepsy
Epilepsy can be a direct manifestation of a primary mitochondrial disorder, including some forms of MELAS, MERRF, Leigh syndrome spectrum, and POLG-related disease.
Seizures can also produce secondary metabolic and oxidative stress. This does not mean that most epilepsy is caused by mitochondrial disease.
Selected-subgroup evidence
Autism and mitochondrial findings
Subgroup evidence must not be converted into a universal explanation.
Autism is a neurodevelopmental condition, not a mitochondrial disease. Selected imaging, metabolic, and genetic studies suggest that mitochondrial or metabolic abnormalities may be relevant to a subset of autistic people.
For example, some studies have identified elevated brain lactate or other metabolic findings in a minority of participants. This may support the existence of selected metabolic subgroups rather than a feature shared by all autistic people.
It does not support a general claim that autism is caused by mitochondrial dysfunction or that a general mitochondrial intervention treats autism.
Immune, Inflammatory, and Post-Infectious Disease
Immune cells reorganize their metabolism as they activate, divide, migrate, produce inflammatory signals, kill pathogens, and return toward a resting state. Mitochondria participate in these shifts, but the meaning of a mitochondrial finding depends heavily on cell type and timing.
Immune activation requires cells to change how they obtain and use energy. Some immune cells increase glycolysis, some rely more heavily on mitochondrial oxidation, and others change their metabolism as they move from activation toward resolution or memory.
Increased mitochondrial activity can therefore reflect activation or compensation. Reduced activity can reflect cellular injury, exhaustion, a change in cell population, or a normal shift in immune state.
The direction of the measurement alone does not establish whether the response is beneficial or harmful. Interpretation requires knowing which cells were tested, when they were tested, and what biological state they were in.
Which immune cells were studied?
T cells, B cells, monocytes, neutrophils, macrophages, and natural killer cells have different metabolic programs and functions.
Were the cells resting or activated?
Activation, proliferation, migration, antibody production, pathogen killing, resolution, and immune memory require different metabolic strategies.
When was the sample collected?
Acute infection, established inflammation, treatment, recovery, and prolonged illness can produce different mitochondrial measurements.
Autoimmune disease
Rheumatoid arthritis and lupus must be discussed separately
Both are autoimmune diseases, but they have different clinical patterns, affected tissues, immune pathways, and mitochondrial findings. They should not be combined into one universal autoimmune mechanism.
Rheumatoid Arthritis
Rheumatoid arthritis is a systemic autoimmune disease that prominently affects synovial joints. Immune cells, fibroblast-like synoviocytes, blood vessels, and surrounding tissue contribute to persistent inflammation and joint damage.
Studies have reported altered redox signaling, mitochondrial metabolism, mitochondrial DNA release, and inflammatory pathway activation in selected cells and joint tissues.
Mitochondrial stress signals may interact with immune activation, synovial-cell behavior, inflammation, and tissue injury.
Findings from one immune-cell population or joint-tissue study do not establish one mitochondrial cause for all rheumatoid arthritis.
Systemic Lupus Erythematosus
Systemic lupus erythematosus, or SLE, can affect the skin, joints, kidneys, nervous system, blood cells, and other organs. Disease activity and organ involvement vary substantially among patients.
Selected studies have reported mitochondrial hyperpolarization, ATP depletion, altered redox signaling, mitochondrial DNA release, and changes in specific T-cell and neutrophil populations.
These changes may interact with abnormal immune activation, inflammatory signaling, autoantibody-related processes, and organ-specific injury.
SLE contains several clinical and immunological subgroups. Findings from one cell type cannot describe every patient or affected organ.
Post-infectious and chronic illness
ME/CFS: why the mitochondrial evidence is considered mixed
Myalgic encephalomyelitis/chronic fatigue syndrome, or ME/CFS, can follow an infection in some people, although triggers and clinical patterns vary. Post-exertional malaise is a central feature and is not equivalent to ordinary tiredness.
Reduced reserve or altered cellular response
Some studies of blood-cell respiration and cellular bioenergetics have reported reduced respiratory reserve, altered responses to energetic stress, or differences in how cells use available fuels.
These findings could be relevant to exercise intolerance or post-exertional symptoms in selected subgroups.
Preserved respiratory-chain function
Other studies have not found a defect in individual respiratory-chain complexes or have reported results that differ from earlier cohorts.
This raises the possibility that abnormalities may occur upstream of mitochondria, only under specific stress conditions, or only in selected patient groups.
Why studies may reach different conclusions
Studies may use different diagnostic criteria and include clinically different participants.
Measurements from mixed blood cells can change as the proportion of each cell type changes.
Nutrients, stimulation, sample handling, and laboratory methods influence respiratory measurements.
Recent-onset, long-standing, mild, and severe illness may not produce the same biological pattern.
Critical illness
Sepsis demonstrates why timing changes interpretation
Sepsis is a life-threatening organ-dysfunction syndrome caused by a dysregulated response to infection. Immune and mitochondrial measurements can change substantially during the intensive-care course.
Immune activation rises
Immune cells may increase metabolic activity as they recognize infection, produce inflammatory signals, migrate, and attempt to control pathogens.
Injury and compensation coexist
Studies may detect increased or reduced respiration depending on cell population, organ dysfunction, treatment, nutrient supply, oxygen delivery, and the point at which the sample is collected.
Immune state changes again
Surviving patients may move toward recovery, persistent inflammation, immune suppression, cellular exhaustion, or a mixture of these states.
Measurement boundary
Blood-cell findings do not describe every organ
Accessibility makes circulating immune cells valuable for research, but their measurements have a defined scope.
A respiration measurement from circulating monocytes or mixed blood cells describes those cells under the conditions of the assay. It does not directly measure mitochondrial function in the heart, kidney, liver, brain, skeletal muscle, or other organs.
Blood-cell composition can also change during infection, inflammation, medication exposure, and recovery. A change in the measured sample may therefore reflect both altered cell function and a different mixture of cells.
Accurate language should identify the cell type, disease phase, treatment context, and assay rather than referring broadly to “whole-body mitochondrial dysfunction.”
Cancer and Metabolic Reprogramming
Cancer requires especially careful language. Tumor cells do not universally have weak, damaged, or inactive mitochondria. Many retain functional mitochondrial respiration and reorganize metabolism to support growth, survival, and adaptation.
Cancer is not one disease. Tumors differ by tissue of origin, genetic changes, oxygen supply, nutrient availability, immune environment, treatment exposure, and stage.
Some tumors rely heavily on glycolysis. Others retain substantial oxidative phosphorylation, and many use both. Cancer cells can also switch metabolic strategies when their environment changes.
The most accurate relationship category is therefore context-dependent metabolic reprogramming, not a universal loss of mitochondrial function.
A necessary correction
The Warburg effect does not mean mitochondria are switched off
A common misunderstanding begins with a real observation but reaches the wrong conclusion.
Cancer cells rely on sugar because their mitochondria no longer work
This interpretation treats increased glucose uptake and lactate production as proof that oxidative phosphorylation has stopped.
It also implies that cancer can be explained as one uniform state of mitochondrial weakness.
Glycolysis and mitochondrial metabolism can operate together
Many tumors use high rates of glucose uptake and lactate production even when oxygen is available. This pattern is commonly called the Warburg effect.
It does not establish that mitochondrial respiration has stopped. Cancer cells can use glycolysis and oxidative phosphorylation at the same time or shift their dependence as conditions change.
Metabolic strategy
Tumors can use several energy and biosynthetic pathways
These strategies are not mutually exclusive. A tumor may use more than one and change its dependence over time.
Rapid glucose use and lactate production
Glycolysis can provide ATP quickly and supply intermediate molecules for biosynthesis. High glycolytic activity may occur even when oxygen is available.
Functional mitochondrial respiration
Oxidative phosphorylation can support ATP production, nutrient oxidation, biosynthesis, redox control, and survival in selected tumors.
Switching as conditions change
Tumor cells may alter fuel use in response to low oxygen, nutrient limitation, immune pressure, metastasis, or treatment.
Direct human evidence
Human tumors show functional and highly variable respiration
Studies using fresh or ex-vivo human tumor material provide a more direct view than cell lines alone.
Observation
Fresh human lung-tumor biopsies have shown both higher- and lower-respiration subgroups.
Meaning
One respiratory profile does not describe all lung tumors. Patient-specific differences may affect metabolic dependence and treatment response.
Observation
Ex-vivo studies of human breast tumors demonstrate functional oxidative phosphorylation.
Meaning
Tumor cells can retain mitochondrial respiratory capacity while also displaying high glucose use and other reprogrammed metabolic features.
Observation
Human colorectal-tumor studies have identified functional oxidative metabolism and patient-specific metabolic dependence.
Meaning
Mitochondrial dependence can vary among tumors that share the same broad diagnostic label.
Functional roles
How mitochondrial pathways can support cancer cells
The exact combination differs by tumor, but the functions can be organized into three broad groups.
Power and building materials
- ATP production
- Intermediates for lipid, protein, and nucleotide synthesis
- Processing of glucose, fatty acids, and amino acids
Redox control and stress response
- Maintenance of redox balance
- Adaptation to low oxygen or limited nutrients
- Communication with cellular stress pathways
Persistence under pressure
- Resistance to programmed cell death
- Survival during invasion or metastasis
- Resistance to selected treatment pressures
Why tumors differ
Metabolic dependence changes with biological context
A metabolic finding should always be tied to the tumor and conditions in which it was measured.
Lung, breast, colorectal, liver, blood, brain, and other cancers arise from different cells and carry different genetic and epigenetic changes.
Different regions of the same tumor may experience different oxygen levels, blood supply, acidity, immune pressure, and fuel availability.
The metabolic demands of initial tumor growth may differ from those required to invade tissue, circulate, colonize another organ, or remain dormant.
Chemotherapy, radiation, targeted treatment, and immunotherapy may eliminate some cells while favoring cells able to adopt a different metabolic strategy.
Interpretation boundaries
What mitochondrial involvement in cancer does not mean
Cancer is not simply low mitochondrial function
Many tumors retain active respiration and may depend on mitochondrial metabolism for growth or survival.
Ordinary mitochondrial dysfunction does not explain all cancer
Cancer develops through diverse genetic, epigenetic, environmental, immune, and tissue-specific processes.
Improving mitochondrial activity is not automatically desirable
In some tumors, mitochondrial metabolism supports the cancer cell. A general concept of “mitochondrial support” cannot be assumed to oppose cancer biology.
A metabolic mechanism does not prove clinical benefit
A pathway may be scientifically important without establishing that modifying it safely improves patient outcomes.
How Mitochondrial Function Is Studied and Diagnosed
There is no single test that measures complete mitochondrial function throughout the body. Research methods examine specific properties in defined samples, while clinical diagnosis integrates symptoms, genetics, laboratory findings, tissue evidence, and alternative explanations.
The word test can refer to very different activities. A research laboratory may measure oxygen consumption in cultured cells. A clinician may order genetic sequencing to identify a pathogenic variant. These tests answer different questions.
Even measurements with similar names may not be interchangeable. Respiration measured in blood cells, skeletal muscle, isolated mitochondria, or a tumor sample reflects different tissues and experimental conditions.
Accurate interpretation begins by separating measurement of a mitochondrial property from diagnosis of a primary mitochondrial disease.
Studying mitochondrial biology
Researchers examine respiration, membrane potential, metabolites, mitochondrial structure, DNA, signaling, and other properties in a specific experimental system.
What is happening in this sample under these conditions?
Diagnosing primary mitochondrial disease
Clinicians evaluate whether a person has a genetically defined disorder and whether the genetic finding explains the observed clinical pattern.
What diagnosis best explains this person’s findings?
Research measurements
Each method reveals one part of mitochondrial biology
No method should be interpreted beyond the property it actually measures.
What it measures
Oxygen consumption by cells, tissues, isolated mitochondria, or permeabilized samples under defined conditions.
What it does not establish alone
A low value does not identify the cause. It may reflect fewer mitochondria, lower cellular demand, impaired respiratory pathways, damaged cells, sample handling, medication effects, or the fuels provided during the assay.
What they measure
Membrane-potential probes estimate the electrochemical gradient across the inner mitochondrial membrane. ATP assays estimate the amount or production rate of cellular energy currency.
What they do not establish alone
A high membrane potential is not always beneficial, and total ATP can come from both mitochondrial and non-mitochondrial pathways. Dye behavior, cell number, and assay conditions also affect results.
What they measure
Metabolomics measures patterns of small molecules. Stable-isotope tracing follows labeled nutrients through metabolic pathways.
What they do not establish alone
Metabolite abundance is often a snapshot rather than a direct measure of metabolic flow. Whole-cell measurements may not reveal which cellular compartment produced the change.
What they measure
Microscopy can examine mitochondrial number, shape, location, networks, and internal structure. Selected imaging tracers can assess aspects of metabolism in living tissue.
What they do not establish alone
Appearance is not identical to function. Fragmented, elongated, numerous, or enlarged mitochondria may reflect adaptation, stress, cell type, or experimental conditions.
Clinical evaluation
Diagnosis is built from converging evidence
The exact order varies with age, symptoms, urgency, and available expertise, but evaluation commonly moves through these connected stages.
Clinical pattern
Clinicians evaluate symptoms, age of onset, progression, affected organs, neurological and muscular findings, hearing or vision changes, endocrine features, medications, exposures, and family history. They also consider more common explanations.
Supporting laboratory and imaging studies
Blood, urine, imaging, cardiac, neurological, hearing, vision, and metabolic studies may identify affected systems or support a mitochondrial hypothesis. Most individual results are supportive rather than diagnostic.
Molecular genetic testing
Modern evaluation commonly uses sequencing capable of examining mitochondrial DNA and relevant nuclear genes. Testing may involve targeted analysis, multigene panels, exome sequencing, genome sequencing, or a combination based on the clinical question.
Targeted tissue or functional testing
Muscle, urine epithelial cells, fibroblasts, liver, or another relevant tissue may be considered when a variant is difficult to detect in blood, when biochemical confirmation is needed, or when the genetic result remains uncertain.
Integrated interpretation
The final conclusion considers whether the variant is pathogenic, whether inheritance and tissue findings fit, whether the phenotype is consistent, and whether another diagnosis provides a better explanation.
Heteroplasmy and sample choice
A negative blood test may not answer every mitochondrial-DNA question
The proportion of a mitochondrial-DNA variant can differ among tissues and may change over time.
Blood can identify many mitochondrial- and nuclear-DNA variants. However, the proportion of some mitochondrial-DNA variants may be low or decline in circulating blood cells.
Urinary epithelial cells can contain higher detectable heteroplasmy than blood for some variants and can sometimes provide a non-invasive additional sample.
A clinically affected tissue may contain a higher variant level or show histological, biochemical, or respiratory-chain abnormalities not evident in blood.
Common tests and biomarkers
What selected results can—and cannot—tell us
Supportive tests can strengthen or weaken a diagnostic hypothesis, but few provide a definitive answer alone.
Lactate and Pyruvate
Elevated lactate may indicate an imbalance between lactate production and clearance and can support a mitochondrial or other metabolic concern in the correct clinical setting.
Lactate can rise with exercise, illness, poor circulation, seizures, medications, sample-collection difficulty, and many non-mitochondrial conditions. It can also be normal in a person with confirmed mitochondrial disease.
GDF-15 and FGF-21
These circulating proteins can be elevated in primary mitochondrial disorders, particularly in some muscle-involving phenotypes, and may help prioritize further evaluation.
They are not specific to one mitochondrial disease and can be influenced by age, inflammation, liver or kidney disease, cancer, cardiovascular stress, and other conditions.
Muscle Biopsy
Histology, histochemistry, respiratory-chain enzyme activity, mitochondrial-DNA content, heteroplasmy, and evidence of other muscle diseases.
Abnormal findings may lack specificity, while a normal biopsy does not exclude every mitochondrial disorder. Sampling, disease stage, tissue selection, and laboratory methods matter.
Variant of Uncertain Significance
A DNA difference was identified, but current evidence is insufficient to classify it as disease-causing or benign.
Family testing, population data, phenotype matching, biochemical studies, RNA or protein analysis, tissue findings, and future scientific evidence may support reclassification.
Evidence convergence
Confidence rises when independent evidence points in the same direction
A strong diagnosis is usually supported by several compatible forms of evidence rather than one dramatic-looking result.
Phenotype
The symptoms, organs affected, age of onset, and progression fit the proposed disorder.
Genetics
A pathogenic or likely pathogenic variant is identified with an inheritance pattern compatible with the condition.
Biological Effect
Biochemical, tissue, RNA, protein, or cellular evidence supports disruption of the expected pathway.
Alternatives
Other genetic, metabolic, neurological, muscular, toxic, and systemic explanations have been considered.
What Treatment Research Does and Does Not Show
Mitochondrial treatment research now includes approved disease-specific therapies, supportive care, rehabilitation, nutritional strategies, small-molecule drugs, and genetic approaches. These categories do not carry the same level of evidence or support the same claims.
A treatment may control symptoms, prevent complications, improve function, alter a biomarker, or slow part of a disease process. These are different outcomes.
An intervention can also be biologically active without producing a meaningful clinical benefit. It may change lactate, respiration, mitochondrial structure, or another laboratory measurement while leaving mobility, fatigue, organ function, or quality of life unchanged.
Accurate interpretation requires matching the conclusion to the exact disease, population, intervention, outcome, and duration that were tested.
Improve daily function
Treatment may reduce seizures, pain, cardiac symptoms, swallowing difficulty, endocrine problems, or another specific manifestation.
Detect and manage risk
Surveillance and early treatment may reduce harm from cardiomyopathy, arrhythmia, diabetes, hearing loss, malnutrition, or respiratory problems.
Change the disease course
A disease-modifying treatment aims to slow progression, preserve function, or alter the underlying disease process—not only relieve a symptom temporarily.
Evidence ladder
Treatment claims should rise only as high as the evidence
Unlike the relationship categories in Chapter 3, this is an ordered hierarchy. Higher levels generally provide stronger evidence for a specific treatment claim.
Regulatory approval for a defined indication
A regulator has reviewed evidence for a specific treatment, disease, population, dose, and outcome. Approval does not mean the therapy works for other mitochondrial disorders or for general mitochondrial dysfunction.
Randomized controlled trial
Randomization and an appropriate comparison group help determine whether observed improvement is caused by the intervention rather than natural variation, expectations, additional care, or differences among participants.
Open-label or externally controlled study
These studies can identify safety signals, possible benefits, and useful outcome measures. Without concurrent randomization, however, treatment effects are more difficult to separate from natural history and selection bias.
Case report or small case series
A dramatic individual response can justify further research, especially in an ultra-rare genetic condition. It cannot show how often the response will occur or whether the treatment caused it.
Cell or animal evidence
Laboratory studies can establish biological plausibility and guide drug design. They do not establish safety, effective dosing, tissue delivery, or clinical benefit in people.
Disease-specific progress
Several therapies now show why precise diagnosis matters
These therapies apply to defined genetic diseases or indications. They do not establish one treatment for mitochondrial disease as a whole.
Defined indication
Approved in the United States to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kilograms.
Evidence boundary
The 2025 approval used the accelerated pathway and was based on improvement in knee-extensor muscle strength, a measure considered reasonably likely to predict patient benefit. A confirmatory randomized trial is required. The approval does not establish elamipretide efficacy for all primary mitochondrial myopathies.
Defined indication
Authorized in the European Union for visual impairment in adolescents and adults with Leber hereditary optic neuropathy, or LHON.
Evidence boundary
Treatment response can vary with timing, disease phase, and the causal mitochondrial-DNA variant. Evidence in LHON does not prove that idebenone treats unrelated neurological, muscular, or metabolic conditions.
Defined indication
Approved in the United States for Friedreich ataxia in adults and adolescents aged 16 years and older.
Evidence boundary
Friedreich ataxia has a direct disease-specific mitochondrial mechanism caused by frataxin deficiency, but it is not a general mitochondrial-DNA disorder. Benefit in this condition cannot be generalized to other mitochondrial diseases.
Standard care
Supportive care is active treatment
A therapy does not have to repair the genetic defect to improve health, function, safety, or quality of life.
Find complications early
Cardiac, endocrine, neurological, respiratory, hearing, vision, kidney, nutritional, and other monitoring can identify treatable complications before they cause greater harm.
Apply established clinical care
Seizures, diabetes, cardiomyopathy, arrhythmias, pain, migraine, movement disorders, swallowing problems, and other manifestations may be treated using appropriate disease- and patient-specific approaches.
Protect growth and nutritional status
Dietitian support, swallowing assessment, management of gastrointestinal problems, and feeding assistance may reduce malnutrition, aspiration risk, and avoidable metabolic stress.
Preserve mobility and independence
Physical therapy, occupational therapy, speech therapy, mobility equipment, energy-management strategies, and individually prescribed activity can support function.
Supplements and metabolic cofactors
A targeted biochemical rationale is different from a general cocktail
Coenzyme Q10, riboflavin, thiamine, carnitine, creatine, alpha-lipoic acid, and other compounds are often discussed together. Their evidence and relevance are not interchangeable.
Confirmed deficiency or defined pathway
A documented nutrient or cofactor deficiency, a genetic defect in a relevant biochemical pathway, or a known treatment-responsive disorder can provide a stronger reason for targeted replacement.
- The biological target is defined.
- Dose and monitoring can be linked to the diagnosis.
- Response can be evaluated using relevant clinical outcomes.
Broad mitochondrial cocktail
Giving several compounds to a heterogeneous group may be biologically plausible, but it becomes difficult to know which ingredient helps, which patients are likely to respond, and whether laboratory changes translate into clinical benefit.
- Formulations and doses vary among centers.
- Controlled trials are often small or inconclusive.
- Supplements can still cause side effects and interactions.
Rehabilitation evidence
Exercise can improve capacity without correcting the mutation
This is an example of meaningful functional treatment that should not be confused with a cure.
Supervised aerobic and resistance programs have improved exercise capacity, strength, and selected quality-of-life measures in small studies of people with mitochondrial myopathy.
Part of the benefit may come from improved conditioning and muscular adaptation rather than correction of the underlying genetic defect. That does not make the benefit unimportant.
Disease subtype, cardiac status, muscle weakness, balance, autonomic symptoms, recent illness, baseline conditioning, and post-exertional responses can all affect what type and intensity of activity is appropriate.
What negative trials teach
Improving a pathway does not guarantee meaningful patient benefit
Negative and inconclusive trials are scientifically valuable because they test whether a plausible mechanism actually changes clinical outcomes.
Coenzyme Q10 in mitochondrial cytopathy
Thirty participants with several mitochondrial disorders received high-dose coenzyme Q10 or placebo. The study measured exercise, lactate, strength, activities of daily living, quality of life, and other outcomes.
Coenzyme Q10 produced minor changes in post-exercise lactate and selected exercise measurements but did not improve several clinically relevant outcomes, including strength.
Elamipretide in primary mitochondrial myopathy
The randomized phase 3 trial enrolled 218 people with genetically confirmed primary mitochondrial myopathy and evaluated walking distance and patient-reported fatigue over 24 weeks.
The study did not establish benefit on its primary walking and fatigue outcomes for the broad trial population, despite earlier smaller studies and a strong mitochondrial mechanism.
Research directions
Future treatment is moving toward greater biological precision
The field increasingly aims to match the treatment strategy to the gene, tissue, molecular defect, and disease stage.
Gene and RNA-based treatment
Research includes nuclear-gene replacement, RNA modification, allotopic expression, and other approaches intended to restore or compensate for a specific genetic function.
Changing mitochondrial-DNA balance
Experimental strategies aim to reduce harmful mitochondrial-DNA variants, shift heteroplasmy, or prevent transmission. Delivery, tissue coverage, durability, and safety remain major challenges.
Smaller, better-defined populations
Genetic stratification, natural-history data, wearable measurements, individualized outcomes, and adaptive trial designs may help detect treatment effects that broad mixed-population studies miss.
Secondary mitochondrial dysfunction
Treating a common disease is not the same as treating primary mitochondrial disease
The treatment conclusion must follow the disease relationship established in Chapters 3 through 9.
In diabetes, heart failure, chronic kidney disease, inflammatory disease, neurodegeneration, and other common conditions, mitochondrial changes may be contributors, consequences, adaptations, or feedback mechanisms.
The strongest clinical approach is usually to treat the underlying diagnosed disease and its established risk factors. A mitochondrial biomarker or laboratory mechanism does not automatically justify replacing proven care with a general mitochondrial intervention.
An intervention aimed at mitochondrial biology must still be tested within the specific disease population and against outcomes that matter to patients.
References and Further Reading
This guide draws from clinical guidelines, regulatory documents, systematic reviews, human studies, laboratory research, and global disease-burden sources. The references below are organized by topic so readers can examine both the evidence and its limitations.
No single publication supports every conclusion on this page. Mitochondrial biology differs across genes, tissues, diseases, research methods, and stages of illness.
Reviews and consensus statements provide broad context. Primary studies provide more direct evidence but usually answer narrower questions. Regulatory documents define authorized indications and should not be generalized beyond the treatment, population, and outcome reviewed.
This is a selected reference library, not a comprehensive systematic review of every mitochondrial mechanism or disease discussed.
Human evidence where available
Human tissue, imaging, clinical, genetic, and interventional studies are prioritized when the page makes claims about human disease.
Guidelines and official sources
GeneReviews, professional consensus statements, public-health agencies, and regulators are used for diagnosis, care, burden, and treatment status.
Sources that preserve uncertainty
Preference is given to publications that distinguish association from causation and laboratory effects from demonstrated clinical benefit.
Selected source library
References organized by evidence area
Open a topic to view its sources. External links open in a new browser tab.
Foundations, Primary Mitochondrial Disease, and Population Context View sources
-
Clinical overview
Primary Mitochondrial Disorders Overview ↗
Overview of primary mitochondrial disease, heteroplasmy, threshold effects, clinical presentation, genetic testing, tissue selection, and genetic counseling.
-
Prevalence study
Prevalence of Nuclear and Mitochondrial DNA Mutations Related to Adult Mitochondrial Disease ↗
Source for the regional estimate of approximately one affected adult in 4,300.
-
Consensus
Diagnosis and Management of Mitochondrial Disease: A Consensus Statement ↗
Consensus recommendations for evaluation, diagnosis, and management of suspected or confirmed mitochondrial disease.
-
Care guideline
Patient Care Standards for Primary Mitochondrial Disease ↗
Organ-specific surveillance and care recommendations from the Mitochondrial Medicine Society.
-
Disease primer
Broad review of genetics, clinical heterogeneity, pathophysiology, diagnosis, and management.
-
Burden data
Global obesity definitions and population estimates used for scale in Chapter 4.
-
Burden data
IDF Diabetes Atlas: Global Diabetes Estimates ↗
Source for the 2024 estimate of 589 million adults aged 20–79 living with diabetes.
-
Public health
Clinical overview and estimated prevalence of 10%–13% among reproductive-aged women.
Metabolic, Cardiovascular, Kidney, and Ischemic Disease View sources
-
Human review
The Role of Mitochondria in Common Metabolic Diseases in Humans ↗
Human-focused review emphasizing that mitochondrial changes may represent adaptation rather than universal impairment.
-
Critique
Review of tissue, method, and context-dependent relationships between mitochondria and insulin sensitivity.
-
Critique
MASH: The Nexus of Metabolism, Inflammation, and Fibrosis ↗
Integrates lipid handling, mitochondrial oxidation, cellular stress, inflammation, and fibrosis in MASH.
-
Critique
Mitochondria and Polycystic Ovary Syndrome ↗
Recent review of mitochondrial, inflammatory, and cellular-stress pathways studied in PCOS.
-
Human tissue
Mitochondrial Dysfunction in Human Hypertrophic Cardiomyopathy ↗
Direct human myocardial evidence linking respiratory abnormalities with cardiomyocyte architecture.
-
Critique
Mitochondrial Dysfunction in the Pathophysiology of Renal Diseases ↗
Review of kidney mitochondrial energetics, quality control, organelle communication, injury, and clinical research.
-
Clinical trial
MITOCARE Study Results: TRO40303 in Acute Myocardial Infarction ↗
Randomized clinical test of a mitochondrial reperfusion-injury strategy that did not reduce the prespecified measures of myocardial injury.
-
Clinical trial
Cyclosporine Before PCI in Patients With Acute Myocardial Infarction ↗
The CIRCUS trial, illustrating the difficulty of translating a mitochondrial reperfusion mechanism into improved clinical outcomes.
Neurological, Immune, Inflammatory, and Post-Infectious Disease View sources
-
Human imaging
Mitochondrial Complex I Abnormalities Associated With Tau and Symptoms in Mild Alzheimer Disease ↗
Human PET-imaging study examining regional mitochondrial complex I, tau, amyloid, and clinical measures.
-
Genetic pathway
The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson Disease ↗
Mechanistic review of the genetically defined PINK1–Parkin mitochondrial quality-control pathway.
-
Human tissue
Mitochondrial Defects in Acute Multiple Sclerosis Lesions ↗
Human-lesion evidence showing respiratory-chain defects in a defined subset of acute MS lesions.
-
Disease review
Mitochondrial and Metabolic Dysfunction in Friedreich Ataxia ↗
Review of frataxin deficiency, iron–sulfur cluster biology, mitochondrial stress, and clinical interventions.
-
Critique
Mitochondrial Dysfunction and Oxidative Stress in Rheumatoid Arthritis ↗
Review of mitochondrial changes across immune cells, synovial cells, inflammation, and joint-tissue injury.
-
Cellular study
Complex V Inefficiency and Dysregulated Mitochondrial Function in ME/CFS Lymphocytes ↗
Cellular study demonstrating one pattern among the varied mitochondrial findings reported in ME/CFS cohorts.
-
Critique
Assessment of Mitochondrial Function and Its Prognostic Role in Sepsis ↗
Review of measurement methods, immune-cell metabolism, disease timing, and the limitations of mitochondrial biomarkers in sepsis.
-
Human study
Increased Mitochondrial Respiratory Capacity in Peripheral Immune Cells During Sepsis ↗
Longitudinal human study illustrating how immune-cell respiratory findings can change during the first week of critical illness.
Cancer Metabolism and Mitochondrial Measurement View sources
-
NCI overview
New Clarity on the Warburg Effect ↗
Accessible explanation of aerobic glycolysis and why it should not be equated with universally inactive mitochondria.
-
Critique
The Warburg Effect: 80 Years On ↗
Review emphasizing functional mitochondria and bioenergetic heterogeneity across tumor types.
-
Human tissue
Mitochondrial Respiration in Human Colorectal and Breast Cancer Clinical Material ↗
Direct evidence that respiratory capacity can remain functional and differently regulated in human tumors.
-
Critique
Metabolic Reprogramming, Sensing, and Cancer Therapy ↗
Review of metabolic plasticity, nutrient sensing, tumor-environment interactions, and treatment research.
-
Methods review
Considerations and Best Practices for Respirometry ↗
Review of the strengths, limitations, reporting standards, and interpretation of oxygen-consumption measurements.
-
Methods review
How and When to Measure Mitochondrial Inner-Membrane Potentials ↗
Explains how probe concentration, plasma-membrane potential, mitochondrial mass, and experimental design can affect membrane-potential measurements.
-
Biomarker review
Biomarkers of Mitochondrial Disorders ↗
Clinical overview of traditional and emerging biomarkers, including the limitations of GDF-15 and FGF-21.
-
Meta-analysis
Accuracy of FGF-21 and GDF-15 for Diagnosing Mitochondrial Disorders ↗
Pooled analysis of diagnostic performance showing promise while preserving the need for clinical and genetic interpretation.
Treatment Evidence and Regulatory Status View sources
-
Regulatory
FDA Accelerated Approval of Forzinity for Barth Syndrome ↗
Official indication and accelerated-approval basis for elamipretide in qualifying patients with Barth syndrome.
-
Regulatory
FDA Ongoing Non-Malignant Accelerated Approvals ↗
Current listing of Forzinity’s required confirmatory trial and post-marketing commitment.
-
Regulatory
Raxone: European Public Assessment Report ↗
Official European authorization and indication for idebenone in LHON-related visual impairment.
-
Regulatory
FDA Approval of Skyclarys for Friedreich Ataxia ↗
Official indication and clinical-evidence summary for omaveloxolone.
-
Clinical trial
A Randomized Trial of Coenzyme Q10 in Mitochondrial Disorders ↗
Randomized crossover trial showing minor physiological effects without improvement in several clinically relevant outcomes.
-
Phase 3 trial
MMPOWER-3: Elamipretide in Primary Mitochondrial Myopathy ↗
Randomized phase 3 trial in 218 participants that did not establish benefit on the primary walking and fatigue outcomes for the broad study population.
Additional Global Disease-Burden Sources View sources
-
Burden data
Global prevalence, incidence, disability, and emergency treatment context for stroke.
-
Burden review
Global Burden of Heart Failure ↗
Review supporting the widely cited estimate of more than 64 million people living with heart failure.
-
GBD analysis
Global Burden of Chronic Kidney Disease and Its Risk Factors ↗
Source for the 2021 estimate of approximately 674 million people affected by chronic kidney disease.
-
Burden data
Global dementia burden and the distinction between dementia as an umbrella term and Alzheimer disease.
-
Public health
Global disease burden, symptoms, care, rehabilitation, and public-health context.
-
Burden data
Global Cancer Burden Growing Amidst Mounting Need for Services ↗
Source for global 2022 cancer incidence, mortality, and five-year prevalence estimates.
Reading scientific evidence
A citation supports only what the study actually tested
A study of cultured cells does not establish a treatment effect in people. A study of blood cells does not directly measure the brain, liver, heart, kidney, muscle, or ovaries. A result from one genetic subtype should not be generalized to every person with the broader disease.
Reviews are useful for understanding a field, but their conclusions depend on the studies they include. Clinical guidelines and regulatory decisions can also change as new evidence becomes available.
The most reliable interpretation identifies the population, tissue, intervention, comparison, outcome, and limits of the evidence.